| |
 |
|
|
|
|
| |
|
|
|
|
|
Drug Pipeline |
|
|
|
|  |  | Robust development pipeline, with 5 product candidates in clinical trials | | | | | | Lead product candidate blinatumomab (MT103), a BiTE antibody targeting CD19, has demonstrated clinically meaningful single-agent activity in patients with acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). The Company plans to initiate a European pivotal trial in adult ALL in mid-2010. A phase 1 trial in NHL is on-going. | | | | | | MT110, a BiTE antibody targeting EpCAM, is currently the subject of a Phase 1 clinical trial in patients with solid tumors. Potent anti-tumor activity has been observed with MT110 in various preclinical in vivo models. | | | | | | | | |
|
|
|
|
|
|
|
|
|
|
Technologies |
|
|
|
|
 |
|
BiTE®
BiTE®
molecules are designed to direct the body´s cytotoxic, or
cell-destroying, T cells against tumor cells and represent a new
therapeutic approach to cancer therapy. |
|
|
|
|
|
SCA (single-chain antibodies)
SCAs
are small antibody fragments, which are cost-effective to produce and
extremely versatile for protein engineering. They provide an ideal
structural basis for the development of novel drug formats as
exemplified by their use in BiTE® drugs. |
|
|
|
|
|
|
|
|
|
|
Management |
|
|
|
|  |  | Christian Itin, PhD, President, Chief Executive Officer and Director | | | | | | Barclay Phillips, Senior Vice President and Chief Financial Officer | | | | | | Patrick A. Baeuerle, PhD, Professor for Immunology, Senior Vice President and Chief Scientific Officer | | | | | Jan Fagerberg, M.D., Senior Vice President and Chief Medical Officer |
| | | | Jens Hennecke, PhD, Senior Vice President Business Development | | | | | Mark Reisenauer, Senior Vice President and Chief Commercial Officer | | | | | Matthias Alder, LL.M, Senior Vice President, General Counsel and Secretary |
|
|
|
|
|
|
|
|
|
|
History |
|
|
|
| | | Micromet AG was founded in 1993 as spin-off from the Institute for Immunology, Munich University, Germany | | | | | | In May 2006, Micromet AG merged with CancerVax Corporation (formerly NASDAQ: CNVX) to form Micromet, Inc. (NASDAQ: MITI). |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
